Compare Amgen, Inc. (AMGN) vs Hubbell (HUBB) Price & Performance

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Hubbell — how do they compare? Amgen, Inc. trades at $443.98 (market cap $240.38B), while Hubbell trades at $439.38 (market cap $24.27B). The key difference: Amgen, Inc. is far larger — about 9.9× Hubbell's market cap, and Amgen, Inc. pays the higher dividend (2.27%). Which is the better fit depends on your goals — on Pluang, investors hold Amgen, Inc. for 73 Days and Hubbell for 8 Days on average.

	AMGN	HUBB
Market Cap	$240.38B	$24.27B
Volume	2,043,553	827,838
Sector	Health	Industrials
52-Week High	$447.28	$557.85
52-Week Low	$291.16	$407.36
Typical Hold Time	73 Days	8 Days
Enterprise Value	$283.70B	$29.43B
Dividend Yield	2.27%	1.24%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $439.26, down 1.79% on the day but maintaining strong technical momentum with bullish moving averages and support at $438. The biopharmaceutical giant demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.29 versus $5.62, revenue growth to $36.75B in 2025, and impressive profitability metrics including 69.52% gross margin and 91.47% ROE. Recent positive Phase 3 results for dazodalibep in Sjögren's disease highlight pipeline progress.

Amgen presents a compelling investment case with strong earnings momentum, diversified therapeutic portfolio, and analyst consensus favoring Buy ratings (53.66%). However, elevated debt levels ($56.55B long-term) and competitive pressures in key markets warrant caution. The stock trades above the consensus price target of $403.79, suggesting near-term valuation concerns despite positive clinical developments.

Hubbell

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

Amgen to report Q3 results after strong Q2 and promising cancer drug study resultsSeeking Alpha · 5 hours agoBullish Amgen appoints David W. Gibbs to its Board, adding expertise from Yum! Brands leadership.PRNewsWire · 19 hours agoBullish Amgen's drug combo cuts death risk by 58% in aggressive lung cancer patients.CNBC · 3 days agoBullish View details →

HUBB

Hubbell Q3 2026 EPS rises 14% on 25% sales growth; raises full-year adjusted EPS outlook.GlobeNewsWire · 8 hours agoBullish $6B Arizona investment aims to boost U.S. copper refining, easing AI and power grid supply bottlenecks.24/7 Wall Street · 3 days agoBullish Hubbell Inc. raises its dividend by 7% to $6.08 per share annually, payable Dec 15, 2026.GlobeNewsWire · 4 days agoBullish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Hubbell

Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.

More comparisons